Analysts Set Expectations for TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($1.58) for the year. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $6.73 million.

Separately, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tango Therapeutics has an average rating of “Buy” and an average price target of $12.20.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $4.74 on Wednesday. The business has a 50-day moving average of $1.88 and a 200 day moving average of $2.40. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02. The stock has a market capitalization of $513.79 million, a price-to-earnings ratio of -4.02 and a beta of 1.24.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $33,000. Stonebrook Private Inc. purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $34,000. Ameriprise Financial Inc. purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $35,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $38,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.